pharmaLevers is proud to have among its clients top 10, top 20 and top 50 Global Pharmaceutical companies as well as MedTech companies and Payers. Discretion is one of pharmaLevers core principle. Consequently, the names of its valued clients are not disclosed.
- Bosshard, K., 2018. Law and Economics of Personalized Medicine - Institutional Levers to Foster the Translation of Personalized Medicine. 1st ed. Wiesbaden: Springer Gabler
- Gnädinger, C., 2017. Value-Based Pricing im Bereich Arzneimittelvergütung - Internationale Ansätze und Implikationen für das Schweizer Preisfestsetzungssystem. MPH thesis, Zürich.
Retrieved from https://www.zoraprod.uzh.ch/id/eprint/152572/1/2017-Gnaedinger.pdf
- Sendyona, S., Odeyemi, I., & Maman, K. (2016). Perceptions and factors affecting pharmaceutical market access: results from a literature review and survey of stakeholders in different settings. Journal of Market Access & Health Policy, 4(1), 31660. http://doi.org/10.3402/jmahp.v4.31660
- Toumi, M., 2017. Introduction to Market Access for Pharmaceuticals. 1st ed. Boca Raton, FL: CRC Press.